Impact of primary disease on outcome after ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia
Auteur(s) :
Kroger, Nicolaus [Auteur]
Eikema, Diderik-Jan [Auteur]
Koster, Linda [Auteur]
Beelen, Dietrich [Auteur]
De Wreede, Liesbeth C. [Auteur]
Finke, Jurgen [Auteur]
Koenecke, Christian [Auteur]
Niederwieser, Dietger [Auteur]
Bornhauser, Martin [Auteur]
Schonland, Stefan [Auteur]
Potter, Victoria [Auteur]
Wolschke, Christine [Auteur]
Maertens, Johan [Auteur]
Theobald, Matthias [Auteur]
Kobbe, Guido [Auteur]
Itala-Remes, Maija [Auteur]
Wulf, Gerald [Auteur]
Kahls, Peter [Auteur]
Forcade, Edouard [Auteur]
Greinix, Hildegard [Auteur]
Masszi, Tamas [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Chalandon, Yves [Auteur]
Robin, Marie [Auteur]
Eikema, Diderik-Jan [Auteur]
Koster, Linda [Auteur]
Beelen, Dietrich [Auteur]
De Wreede, Liesbeth C. [Auteur]
Finke, Jurgen [Auteur]
Koenecke, Christian [Auteur]
Niederwieser, Dietger [Auteur]
Bornhauser, Martin [Auteur]
Schonland, Stefan [Auteur]
Potter, Victoria [Auteur]
Wolschke, Christine [Auteur]
Maertens, Johan [Auteur]
Theobald, Matthias [Auteur]
Kobbe, Guido [Auteur]
Itala-Remes, Maija [Auteur]
Wulf, Gerald [Auteur]
Kahls, Peter [Auteur]
Forcade, Edouard [Auteur]
Greinix, Hildegard [Auteur]
Masszi, Tamas [Auteur]
Yakoub-Agha, Ibrahim [Auteur]

Lille Inflammation Research International Center - U 995 [LIRIC]
Chalandon, Yves [Auteur]
Robin, Marie [Auteur]
Titre de la revue :
British Journal of Haematology
Nom court de la revue :
Br. J. Haematol.
Numéro :
185
Pagination :
725-732
Date de publication :
2019-05
ISSN :
1365-2141
Mot(s)-clé(s) en anglais :
allogeneic stem cell transplantation
MDS
secondary acute myeloid leukaemia
chronic myelomonocytic leukaemia
myeloproliferative neoplasm
MDS
secondary acute myeloid leukaemia
chronic myelomonocytic leukaemia
myeloproliferative neoplasm
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukaemia (CMML) can progress to secondary acute myeloid leukaemia (sAML). We compared the outcome of 4214 sAML patients who ...
Lire la suite >Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukaemia (CMML) can progress to secondary acute myeloid leukaemia (sAML). We compared the outcome of 4214 sAML patients who received allogeneic haematopoietic stem cell transplantation (allo-HSCT) from an unrelated (62%) or human leucocyte antigen (HLA)-identical sibling donor (38%) according the underlying disease: MDS (n = 3541), CMML (n = 251) or MPN (n = 422). After a median follow up of 46·5 months, the estimated 3-year progression-free (PFS) and overall survival (OS) for the entire group was 36% (34-37%) and 41% (40-43%), respectively. The cumulative incidence of relapse and non-relapse mortality (NRM) was 37% (35-39%) and 27% (26-29%), respectively. In a multivariable analysis for OS, besides age (P < 0·001), unrelated donor (P = 0·011), cytomegalovirus ± constellation (P = 0·007), Karnofsky index ≤ 80 (P < 0·001), remission status (P < 0·001), peripheral blood as stem cell source (P = 0·009), sAML from MPN (P = 0·003) remained a significant factor in comparison to sAML from MDS, while worse outcome of sAML from CMML did not reach statistical significance (P = 0·06). This large registry study demonstrates a major impact of the underlying disease on outcome of sAML after allo-HSCT.Lire moins >
Lire la suite >Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukaemia (CMML) can progress to secondary acute myeloid leukaemia (sAML). We compared the outcome of 4214 sAML patients who received allogeneic haematopoietic stem cell transplantation (allo-HSCT) from an unrelated (62%) or human leucocyte antigen (HLA)-identical sibling donor (38%) according the underlying disease: MDS (n = 3541), CMML (n = 251) or MPN (n = 422). After a median follow up of 46·5 months, the estimated 3-year progression-free (PFS) and overall survival (OS) for the entire group was 36% (34-37%) and 41% (40-43%), respectively. The cumulative incidence of relapse and non-relapse mortality (NRM) was 37% (35-39%) and 27% (26-29%), respectively. In a multivariable analysis for OS, besides age (P < 0·001), unrelated donor (P = 0·011), cytomegalovirus ± constellation (P = 0·007), Karnofsky index ≤ 80 (P < 0·001), remission status (P < 0·001), peripheral blood as stem cell source (P = 0·009), sAML from MPN (P = 0·003) remained a significant factor in comparison to sAML from MDS, while worse outcome of sAML from CMML did not reach statistical significance (P = 0·06). This large registry study demonstrates a major impact of the underlying disease on outcome of sAML after allo-HSCT.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Date de dépôt :
2024-01-30T10:27:36Z
2024-01-30T15:21:23Z
2024-01-30T15:21:23Z